Actively Recruiting
Evaluating TAK-242 and G-CSF With Standard Therapy for Severe Alcoholic Hepatitis and Acute-on-Chronic Liver Failure in a Randomized, Placebo-Controlled Trial
Led by Yaqrit Ltd · Updated on 2026-09-21
78
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new combination of drugs, TAK-242 and G-CSF, alongside standard therapy to treat acute-on-chronic liver failure ACLF in patients with severe alcoholic hepatitis sAH. ACLF is a serious condition involving sudden liver function decline and complications such as jaundice, fluid buildup, and brain dysfunction, often leading to organ failure and increased risk of death within 28 days to three months. TAK-242 aims to block an excessive immune response, while G-CSF encourages liver cell growth to improve patient outcomes. This Phase 2 randomized, double-blind, placebo-controlled trial includes 78 hospitalized patients with sAH and ACLF. Participants are assigned to one of three groups standard care with placebo, standard care with TAK-242 infusion for 10 days plus placebo for G-CSF, or standard care with TAK-242 plus G-CSF injections for six doses over the first 8 days. The investigational medications include continuous IV infusion of TAK-242 and daily subcutaneous injections of G-CSF. The study also evaluates how the drugs affect the body and their processing within it. Participants will be monitored during hospitalization with follow-up visits on Days 14, 28, and 84 after enrollment. Assessments include clinical evaluations, blood tests, and measurement of liver function and inflammation markers. Researchers will track safety, changes in disease severity scores, organ function, survival rates, and quality of life over approximately 86 days of participation. An independent board will review safety and pharmacokinetic data early in the study to ensure patient wellbeing.
CONDITIONS
Brief Title
A-TANGO Phase 2 Study
Research Team
M
Monica Razdan
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here